

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Catapano Alberico	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular (2014)</li> <li>- Esteve : Cardiovascular (2014)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2014-2015-2016)</li> <li>- Kowa : Cardiovascular (2014-2015-2016)</li> <li>- Astra Zeneca : Cardiovascular (2014-2016)</li> <li>- Pfizer : Cardiovascular (2014-2016)</li> <li>- Sanofi Aventis : Cardiovascular (2014-2016)</li> <li>- Aatra Zeneca : Cardiovascular (2015)</li> <li>- Recordati International : Cardiovascular (2015-2016)</li> <li>- Amgen Inc : Cardiovascular (2016)</li> <li>- Aegerion : Cardiovascular (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular (2015)</li> <li>- Pfizer : Cardiovascular (2015)</li> <li>- Sanofi Aventis : Cardiovascular (2015)</li> <li>- Aegerion : Cardiovascular (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : Cardiovascular (2015-2016)</li> <li>- Sanofi Aventis : Cardiovascular (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2015-2016)</li> </ul>
Chapman John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lilly : dyslipidemia (2014)</li> <li>- Merck Sharp &amp; Dohme : dyslipidemia (2014)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Chapman John	<ul style="list-style-type: none"> <li>- Kowa : dyslipidemia (2014)</li> <li>- cerenis : HDL (2014)</li> <li>- Amgen : hypercholesterolemia (2014)</li> <li>- Sanofi Aventis : hypercholesterolemia (2014)</li> <li>- Regeneron : hypercholesterolemia (2014)</li> <li>- Astra Zeneca : hypertriglyceridemia (2014)</li> <li>- Unilever : nutraceuticals (2014)</li> <li>- Unilever : human Nutrition and CVD (2015)</li> <li>- Kowa : lipid lowering and CVD (2015)</li> <li>- MSD : lipid lowering and CVD (2015)</li> <li>- Astrazeneca : lipid lowering, dyslipidemia and CVD (2015)</li> <li>- Amgen : PCSK9 inhibition (2015)</li> <li>- Sanofi-Regeneron : PCSK9 inhibition (2015)</li> <li>- Servier : Atherosclerotic vascular disease (2016)</li> <li>- Unilever : Lipid lowering (2016)</li> <li>- Amgen : Lipid lowering therapies (2016)</li> <li>- Sanofi-Regeneron : Lipid lowering therapies (2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Kowa : dyslipidemia (2014)</li> <li>- Pfizer : diabetic dyslipidemia (2014-2015)</li> <li>- Kowa : Lipid lowering, dyslipidemia and CVD (2015)</li> <li>- Pfizer : Statins (2016)</li> <li>- Kowa : Statins (2016)</li> </ul> </li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Cooney Marie Therese	Nothing to be declared (2014-2015-2016)
De Backer Guy	Nothing to be declared (2014-2016) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Lipid lowering drugs (2015) - Sanofi Aventis : Lipid lowering drugs (2015)
Drexel Heinz	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck and others : diabetes, hypertension, lipids (2014-2015-2016)
Graham Ian Maklim	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Advisory Board (2014-2015) - Merck Sharp & Dohme : CVD risk factor audit (2014-2015) - MSD : Prevention and risk assessment (2016) D - Research funding (departmental or institutional). - Merck Sharp & Dohme : CVD risk factor audit (2014) E - Research funding (personal). - World Health Organisation : Co-Chair of Expert Advisory Group developing a new CVD risk estimation system (2015)
Hoes Arno	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014) - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014) D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hoes Arno	<p>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015-2016)</p>
Jennings Catriona Sian	<p>Nothing to be declared (2014-2015-2016)</p>
Landmesser Ulf	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Advisory Board, Speakers fee (2014)</li> <li>- Sanofi Aventis : Advisory Board, Speakers fee (2014)</li> <li>- MSD : Advisory Board, Speakers fee (2014)</li> <li>- Roche Pharma : Research grant, Advisory Board (2014)</li> <li>- Pfizer : Research grant, Speakers fee (2014)</li> <li>- St. Jude : Advisory Board fees (2015-2016)</li> <li>- Amgen : Speaker fees (2015-2016)</li> <li>- Pfizer : Speaker fees (2015-2016)</li> <li>- Sanofi Aventis : Speaker fees (2015-2016)</li> <li>- Berlin Chemie AG : Speaker fees (2015-2016)</li> <li>- Roche Pharma : Speaker fees (2015-2016)</li> <li>- MSD : Speaker fees, Advisory Board fees (2015-2016)</li> <li>- Boehringer-Ingelheim : Speaker fees (2016)</li> </ul>
Pedersen Terje	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lipid lowering drugs (2014)</li> <li>- Amgen : PCSK9 inhibitor (under development) (2014)</li> <li>- Amgen : Cholesterol lowering (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pedersen Terje	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Cholesterol lowering (2015-2016)</li> <li>- Sanofi Aventis : Cholesterol lowering (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lipid lowering drugs (2014)</li> <li>- Amgen : PCSK9 inhibitor (under development) (2014)</li> <li>- Merck Sharp &amp; Dohme : Cholesterol lowering (2015)</li> <li>- Amgen : Cholesterol lowering (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Cholesterol lowering (2016)</li> <li>- Merck Sharp &amp; Dohme : Cholesterol lowering (2016)</li> </ul>
Reiner Zeljko	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Synageva : LAL-D (2014)</li> <li>- Sanofi Aventis : PCSK9 inhibitor (2014)</li> <li>- Sanofi Aventis : PCSK9 inhibitor (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Mylan : antilipemics (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : mipomersen (2014)</li> </ul>
Riccardi Gabriele	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : diabetes (2014-2015-2016)</li> <li>- Takeda Pharmaceuticals : diabetes (2014-2015-2016)</li> <li>- Aventis : diabetes (2014-2015-2016)</li> <li>- Barilla Center for food and nutrition Foundation : nutrition (2014-2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Barilla Food Company : nutrition (2014-2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Riccardi Gabriele	D - Research funding (departmental or institutional). - Barilla Food Company : nutrition (2014-2015-2016)
Taskinen Marja-Riitta	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : PCSK9 anti-sense (2014) - Chiesi Pharma : Glybera (2014-2015-2016) - Amgen : PCSK9 anti-sense (2014-2015-2016) - Sanofi Aventis : PCSK9 anti-sense (2014-2015-2016) - Astra Zeneca : Rosuvastatin (2014-2015-2016)  D - Research funding (departmental or institutional). - Merck Sharp & Dohme : CETP inhibitor (2014-2015-2016) - Sanofi Aventis : PCSK9 anti-sense (2014-2015-2016) - Novo-Nordisk : GLP1-analogue (2015-2016)
Tokgozoglulale	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Kowa : dyslipidemia (2014) - Menarini-IE : coronary artery disease (2014-2015) - Daiichi Sankyo : antiplatelet (2014-2015-2016) - Sanofi Aventis : antiplatelet, lipid (2014-2015-2016) - GlaxoSmithKline : antithrombotic (2014-2015-2016) - Abbott : dyslipidemia (2014-2015-2016) - Astra Zeneca : dyslipidemia, hypertension, antiplatelet, pulmonary hypertension (2014-2015-2016) - Novartis : heart failure (2014-2015-2016) - Servier : hypertension (2014-2015-2016) - Amgen : lipid (2014-2015-2016) - Merck Sharp & Dohme : lipid (2014-2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tokgozoglulale	<ul style="list-style-type: none"> <li>- Aegerion : lipid (2014-2015-2016)</li> <li>- Pfizer : lipids (2014-2015-2016)</li> <li>- Bayer : pulmonary htn (2014-2015-2016)</li> <li>- Actelion : pulmonary hypertension (2014-2015-2016)</li> <li>- Boehringer-Ingelheim : thrombosis (2014-2015-2016)</li> <li>- Mylan : dyslipidemia (2015-2016)</li> </ul>
Verschuren Monique	Nothing to be declared (2014-2015-2016)
Vlachopoulos Charalambos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Perindopril (2014)</li> <li>- Bayer : Rivaroxaban (2014)</li> <li>- Medtronic : Stents (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- OMRON Healthcare : Hypertension (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> <li>- Boehringer-Ingelheim : Dabigatran (2014-2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Ezetimibe (2014-2015-2016)</li> <li>- PharmaSwiss : Hypertension (2014-2015-2016)</li> <li>- Menarini : Angina (2015)</li> <li>- ELPEN : Hypertension (2015)</li> <li>- Merck Serono : Hypertension-Arrhythmias (2015)</li> <li>- Amgen : Dyslipidemia (2015-2016)</li> <li>- Angelini : Dyslipidemia (2015-2016)</li> <li>- Menarini : Erectile Dysfunction (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vlachopoulos Charalambos	<ul style="list-style-type: none"> <li>- Novartis : Hypertension (2015-2016)</li> <li>- Sanofi Aventis : Hypertension (2015-2016)</li> <li>- Servier : Hypertension-Dyslipidemia (2015-2016)</li> <li>- Menarini : Angina - Erectile Dysfunction (2016)</li> <li>- Mylan : Dyslipidemia (2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Bayer : Hormone Replacement (2016)</li> </ul>
Wiklund Olov	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : cardiovascular prevention (2014)</li> <li>- Boehringer-Ingelheim : Cardiovascular prevention (2014-2015)</li> <li>- Astra Zeneca : Cardiovascular prevention (2014-2015-2016)</li> <li>- Amgen Inc : cardiovascular prevention (2014-2015-2016)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular prevention (2014-2015-2016)</li> <li>- Sanofi Aventis : vardiovascular prevention (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Quintiles : Diabetes (2014)</li> <li>- Astra Zeneca : Basic cardiovascular (2014-2015)</li> <li>- DuPont : Cardiovascular (2014-2015)</li> <li>- Cebix inc : Diabetes (2014-2015)</li> <li>- Sanof-Aventis : Cartdiovascular (2015)</li> </ul>
Wood David Allan	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Lipid modification (2014)</li> <li>- Merck Sharp &amp; Dohme : Niacin - Lipid modification (2014)</li> </ul>



## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wood David Allan	<ul style="list-style-type: none"> <li>- CME project of ESC and Irish Cardiac Society : Stable CAD / EA IV (2014)</li> <li>- Amgen : Lipid lowering (2015)</li> <li>- Astra Zeneca : Lipid lowering (2015)</li> <li>- Ferrer Internacional : Polypill (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- European Society of Cardiology : EUROASPIRE IV (2014)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - TASK FORCE

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"><li>- Ikaria : Clinical trial (2014-2015)</li><li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li><li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li></ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Thermo Fischer Scientific : Cardiac markers (2015) - Vifor International : Heart failure (2015) - Astra Zeneca : Platelet inhibition (2015) - Astra Zeneca : Antiplatelet treatment (2016)
Badimon Lina	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Lipids (2015-2016) - Burson Masteller : Nutrition (2015-2016) - Astra Zeneca : Thrombosis (2015-2016) D - Research funding (departmental or institutional). - Astrazeneca : Thrombosis (2015-2016)
Baron Esquivias Gonzalo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2015-2016) - Daiichi Sankyo : Anticoagulation (2015-2016) - Pfizer : Anticoagulation (2015-2016) - Merck Sharp & Dohme : Dyslipemia (2015-2016) - Bayer : Anticoagulation (2016)
Benlamin Hisham	Nothing to be declared (2015-2016)
Boren Jan	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Metabolism (2015-2016) - Eli Lilly : Metabolism (2015-2016) - Sanofi Aventis : Metabolism (2015-2016) - MSD : Metabolism (2015-2016) - NovoNordisk : Metabolism (2015-2016) D - Research funding (departmental or institutional). - Astra Zeneca : Metabolism (2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Boren Jan	<ul style="list-style-type: none"> <li>- Novo-Nordisk : Metabolism (2015-2016)</li> </ul>
Bruckert Eric	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lipid (2015)</li> <li>- Danone : Lipid (2015)</li> <li>- Aegerion : Lipid (2015)</li> <li>- Rottapharm : Lipid (2015)</li> <li>- Amgen : Lipid (2015-2016)</li> <li>- Astra Zeneca : Lipid (2015-2016)</li> <li>- Sanofi Aventis : lipid (2015-2016)</li> <li>- Lilly : Lipid (2015-2016)</li> <li>- Chiesi Pharma : Lipid (2015-2016)</li> <li>- Unilever : Lipid (2015-2016)</li> <li>- Regeneron : lipid (2015-2016)</li> <li>- Meda pharma : Lipid (2016)</li> <li>- Genfit SA : Lipid (2016)</li> <li>- MSD : Lipid (2016)</li> <li>- Ionis pharmaceuticals : Lipid (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : lipid (2016)</li> <li>- Aegerion : Lipid (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Lipid (2015)</li> <li>- Danone : lipid (2015)</li> <li>- Aegerion : Lipid (2015)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bruckert Eric	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Lipid (2016)</li> </ul>
Claeys Marc	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : prasugrel, abciximab (2015-2016)</li> <li>- Bayer : rivaroxabam (2015-2016)</li> <li>- Abbott Vascular : stents- mitraclip (2015-2016)</li> <li>- Astra Zeneca : ticagrelor (2015-2016)</li> </ul>
Cordero Alberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Advisory Board (2015)</li> <li>- Sanofi Aventis : Advisory Board (2015)</li> <li>- Astra Zeneca : Consultancy and Speaker fee (2015)</li> <li>- Ferrer Spain : Consultancy and Speaker fee (2015)</li> <li>- Sanofi Aventis : Dyslipidemia (2016)</li> <li>- Amgen Inc : Dyslipidemia (2016)</li> </ul>
Corsini Alberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular (2015-2016)</li> <li>- Astra Zeneca : Cardiovascular (2015-2016)</li> <li>- Pfizer : Cardiovascular (2015-2016)</li> <li>- Bristol Myers Squibb : cardiovascular (2015-2016)</li> <li>- Mediolanum : Cardiovascular (2015-2016)</li> <li>- Sanofi Aventis : Cardiovascular (2016)</li> <li>- Recordati International : Cardiovascular (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Regeneron : cardiovascular (2015-2016)</li> <li>- Polichem : Cardiovascular (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Corsini Alberto	- Rottapharm : Metabolism (2015-2016)
Dingli Philip	Nothing to be declared (2015-2016)
Ezhov Marat	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Atherosclerosis (2015-2016)
Faouzi Addad	Nothing to be declared (2015-2016)
Ferrieres Jean	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab (2015-2016) - Cerenis therapeutics : Atherosclerosis (2015-2016) - Amgen : evolocumab (2015-2016) - Merck Sharp & Dohme : ezetimibe (2015-2016) - Aegerion : Lomitapide (2016)
Fras Zlatko	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : cardiovascular drugs (ivabradine, ACE inhibitors) (2015) - Mylan : cardiovascular prevention drugs (fenofibrate, simvastatin) (2015) - Krka Pharma : cardiovascular prevention drugs (statins, ACE inhibitors) (2015) - Merck Sharp & Dohme : ezetimibe (2015) - Sanofi Aventis : alirocumab (2015-2016) - Amgen : evolocumab (2015-2016) - Astra Zeneca : ticagrelor (2015-2016) - Boehringer-Ingelheim : empagliflozin (diabetes & CVD) (2016)  E - Research funding (personal). - Duke Clinical Research Institute : alirocumab (2015-2016)
Funk-Brentano Christian	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Intracellular Therapies USA : Cardiac Safety of non-cardiovascular products (2015) - Bristol Myers Squibb (USA) : Cardiac safety of antiviral drugs (2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Funck-Brentano Christian	<ul style="list-style-type: none"> <li>- Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2015-2016)</li> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2015-2016)</li> <li>- Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2015-2016)</li> <li>- MMV (CH) : Cardiac Safety of two antimalarial drugs (2015-2016)</li> <li>- Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology (2015-2016)</li> </ul>
Georgiou Georgios C	Nothing to be declared (2015-2016)
Giannuzzi Pantaleo	Nothing to be declared (2015-2016)
Gudnason Thorarinn	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : NOAC (2015)</li> </ul>
Gueyffier Francois	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Diabetes (2015-2016)</li> <li>- Teva Pharmaceutical Industries : Multiple sclerosis (2015-2016)</li> <li>- Portola Pharmaceuticals : Thrombosis (2015-2016)</li> <li>- EryTech Pharma : Drugs encapsulated in red cells (2016)</li> </ul>
Henkin Yaakov	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : apixaban (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Ezetimibe (2015-2016)</li> <li>- Sanofi Aventis : Praluent (2015-2016)</li> <li>- Amgen Inc : Repatha (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : ODYSSEY trial (2015-2016)</li> </ul>
Hovland Anders	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Lipid Lowering (2015)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hovland Anders	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Lipid Lowering (2015)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Amgen : Lipid Lowering (2015)</li> <li>- Sanofi Aventis : Lipid lowering (2015)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Amgen : Lipid lowering (2016)</li> </ul> </li> </ul>
Ibrahimi Pranvera	Nothing to be declared (2015-2016)
Ibrahimov Firdovsi	Nothing to be declared (2015-2016)
Ivanov Victoria	Nothing to be declared (2015-2016)
Kayikcioglu Meral	<ul style="list-style-type: none"> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Abbott : cardiovascular (2015-2016)</li> <li>- Pfizer : cardiovascular (2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2015-2016)</li> <li>- Genzyme : cardiovascular (2015-2016)</li> <li>- Amgen : pcsk-9 (2015-2016)</li> <li>- Aegerion : lomitapide for homozygous hypercholesterolemia (2016)</li> </ul> </li> </ul>
Kedev Sasko	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Boston Scientific : Speaker fees (2015-2016)</li> <li>- Medtronic : Speaker fees (2015-2016)</li> <li>- Terumo Inc : Speaker fees (2015-2016)</li> <li>- Meril : Speaker fees (2015-2016)</li> </ul> </li> </ul>
Kervinen Kari	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Acute coronary syndrome (2015)</li> <li>- Abbott : MitraClip (2015)</li> <li>- Amgen : Hyperlipidemia (2016)</li> </ul> </li> </ul>



## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kervinen Kari	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Interventional Cardiology (2016)</p>
Kintscher Ulrich	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Anti-thrombotic therapy and Anti-dyslipidemia therapy (2015) - Berlin Chemie AG : Hypertension (2015-2016) - Sanofi Aventis : Dyslipidemia (2016)</p> <p>D - Research funding (departmental or institutional). - Bayer : Heart Failure (2015)</p>
Kiss Robert Gabor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : apixaban (2015) - Boehringer-Ingelheim : dabigatran (2015) - Bayer Healthcare : rivaroxaban (2015) - Sanofi Aventis steering committee member : coordination of a PCSK9 study (2016) - TIMI group steering committee member : diabetes drug therapy (2016) - Cleveland Clinic Research Foundation : fish oil (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - TIMI group : steering committee member (2015) - Boehringer-Ingelheim : NOAC (2016) - Pfizer : NOAC (2016) - Bayer AG : NOAC (2016) - MSD : sitagliptin, ezetimibe (2016)</p>
Klausen Ib Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Advisory board (has left) (2015) - Sanofi Aventis : Advisory board (has left) (2015) - Astra Zeneca : Speaker (2015-2016) - MSD : Speaker (2015-2016)</p>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Klausen Ib Christian	<ul style="list-style-type: none"> <li>- Amgen : Speaker (2016)</li> <li>- Sanofi Aventis : Speaker (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Primary Investigator (2015)</li> <li>- Astra Zeneca : Primary Investigator (2015)</li> <li>- Pfizer : Primary Investigator (2015)</li> <li>- Sanofi Aventis : Primary Investigator (2015)</li> <li>- MSD : Primary Investigator (2015)</li> <li>- Astra Zeneca : PI (2016)</li> <li>- Sanofi Aventis : PI (2016)</li> <li>- MSD : PI (2016)</li> <li>- Phizer : PI (2016)</li> </ul>
Krstacic Goran	Nothing to be declared (2015-2016)
Latkovskis Gustavs	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants (2015-2016)</li> <li>- Boehringer-Ingelheim : Anticoagulants (2015-2016)</li> <li>- Berlin Chemie AG : Antihypertensive agents (2015-2016)</li> <li>- Sanofi Aventis : Antihypertensive therapies, risk estimation and management, prevention (2015-2016)</li> <li>- Merck Serono : Beta blockers (2015-2016)</li> <li>- University of Latvia : Education (2015-2016)</li> <li>- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2015-2016)</li> <li>- Siemens Healthcare : hs-troponin I (2015-2016)</li> <li>- Servier : Hypertension, heart rate (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Latkovskis Gustavs	<ul style="list-style-type: none"> <li>- Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015-2016)</li> <li>- Mylan : Lipid lowering therapies (2015-2016)</li> <li>- Astra Zeneca : lipid-lowering drugs, anti platelets (2015-2016)</li> <li>- Amgen : Lipid-lowering. (2015-2016)</li> <li>- Riga Stradins University : Postgraduate education (2015-2016)</li> <li>- Menarini : Antihypertensive therapy (2016)</li> <li>- Abbott Laboratories : Cardiac markers (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Merck Serono : bisoprolol and amlodipine combination (2015-2016)</li> <li>- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2015-2016)</li> </ul>
Lettino Maddalena	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Statins, ezetimibe (2015)</li> <li>- Boehringer-Ingelheim : Anticoagulants (2015-2016)</li> <li>- Aspen : Anticoagulants (2015-2016)</li> <li>- Pfizer : Anticoagulants, statins (2015-2016)</li> <li>- Eli Lilly : Antithrombotic agents (2015-2016)</li> <li>- Daiichi Sankyo : Antithrombotic agents, anticoagulants (2015-2016)</li> <li>- Bayer Healthcare : Antithrombotic agents, anticoagulants (2015-2016)</li> <li>- Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2015-2016)</li> <li>- Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (PCK9 inhibitors) (2015-2016)</li> <li>- Astra Zeneca : Antithrombotic agents, statins (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lionis Christos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Pneumococcal vaccination (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Janssen - Cilag Pharmaceutical SACI : Advisory Board fees (topic relevant to common mental disorders) (2015) - Vianex : Advisory Board fees (topic relevant to vaccinations in adults) (2015) - Pfizer International Operations : Advisory Board fees (topic relevant to vaccinations in adults) (2015)</p> <p>D - Research funding (departmental or institutional). - ELPEN S.A. : Observational (epidemiological) Study on metabolic syndrome (2015) - European Commission, Third Programme for the Union's action in the field of health (2014-2020) : European Refugees-Human Movement and Advisory Network (Eur-human) (2016) - Olvos S.A. : Postmarket evaluation of the effectiveness of the extract preparation of 3 Cretan herbs (Cretan lama) (2016)</p>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : atrial fibrillation (2015) - Biotronik : atrial fibrillation (2015) - Boehringer-Ingelheim : atrial fibrillation, thrombosis (2015) - Daiichi Sankyo : atrial fibrillation, thrombosis (2015) - Pfizer : atrial fibrillation, thrombosis (2015) - Bayer Healthcare : atrial fibrillation, thrombosis (2015) - Bristol Myers Squibb : atrial fibrillation, thrombosis (2015) - Medtronic : AF screening (2016) - BMS/Pfizer : Anticoagulation (2016) - Daiichi-Sankyo : Anticoagulation (2016) - Boehringer Ingelheim : Anticoagulation (2016) - Bayer/Janssen : Anticoagulation (2016)</p> <p>D - Research funding (departmental or institutional). - Daiichi Sankyo : atrial fibrillation, thrombosis (2015)</p>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> <li>- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)</li> </ul>
Mach Francois	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure (2015)</li> <li>- Menarini : Hypertension (2015)</li> <li>- Sanofi Aventis : Lipid lowering (2015)</li> <li>- Merck Sharp &amp; Dohme : Lipid lowering (2015)</li> <li>- Astra Zeneca : Lipid lowering, Hypertension, Heart Failure (2015)</li> <li>- Daiichi Sankyo : Lipid lowering, NOAC (2015)</li> <li>- Pfizer : Lipid lowering, NOAC (2015)</li> <li>- Bayer : NOAC (2015)</li> <li>- Boehringer-Ingelheim : NOAC (2015)</li> <li>- Bristol Myers Squibb : NOAC (2015)</li> <li>- Amgen : Lipid lowering (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD : lipid lowering (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lipid lowering (2015)</li> <li>- Amgen : Lipid lowering (2015-2016)</li> </ul>
Maher Vincent	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD : Speaker Honoraria (2015-2016)</li> <li>- Servier speaker honoraria : Speaker Honoraria (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : FH Network (2015-2016)</li> </ul>
Marques-Vidal Pedro	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Swiss national fund : PhD scholarship (2015)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Marques-Vidal Pedro	D - Research funding (departmental or institutional). - Swiss national funds : PhD scholarship (2016)
Marzal Domingo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulants (2015-2016) - Pfizer : Anticoagulants (2015-2016) - Bayer Healthcare : Anticoagulants (2015-2016) - Bristol Myers Squibb : Anticoagulants (2015-2016) - Astra Zeneca : Antiplatelets therapy (2015-2016) - Daiichi Sankyo : Antiplatelets therapy (2015-2016) - Merck Sharp & Dohme : Dyslipidaemias (2015-2016) - Novartis : Heart Failure (2015-2016) - Laboratorios Rovi : Heart Failure (2015-2016) - Servier : Ischaemic cardiomyopathy (2015-2016) - Spanish Society of Cardiology : Ischaemic cardiomyopathy (2015-2016) - Menarini : Ischaemic cardiomyopathy (2015-2016)  D - Research funding (departmental or institutional). - Novartis : Heart Failure (2015-2016)  E - Research funding (personal). - Novartis : Heart Failure (2015-2016)
Milicic Davor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Diagnostics : Biomarkers (2015-2016) - Heartware : LVAD (2015-2016) - Boehringer-Ingelheim : NOACS (2015-2016) - Bayer Healthcare : NOACS (2015-2016) - Amgen : PCSK9 inhibitors (2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Milicic Davor	- Astra Zeneca : Ticagrelor (2015-2016)
Mirrakhimov Erkin	Nothing to be declared (2015-2016)
Mitchenko Olena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Dyslipidemia (2015-2016)
Mureddu Gian Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bristol Myers Squibb : cardiovascular diagnostic systems (2015-2016) - Boehringer-Ingelheim : cardiovascular pharmaceutical (2015-2016) - Servier : cardiovascular pharmaceutical (2015-2016) - Bayer Healthcare : cardiovascular pharmaceutical (2015-2016) - Malesci : cardiovascular pharmaceutical (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bristol Myers Squibb : cardiovascular pharmaceutical (2015-2016)
Mussagaliyeva Aisulu	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Stable angina (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Stable angina (2015-2016)
Nedeljkovic Milan	Nothing to be declared (2015-2016)
Nilsson Lennart	Nothing to be declared (2016)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Lipidology (2015) - Sanofi Aventis : Lipidology (2015) - Merck Sharp & Dohme : Lipidology (2015)
Pedro Botet Montoya Juan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Esteve : Alipza (2015) - Sanofi Aventis : Alirocumab (2015)  - MSD : Inegy, Atozet (2015)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pedro Botet Montoya Juan	<ul style="list-style-type: none"> <li>- Mylan : Pravafenix 40/160 (2015)</li> <li>- Astra Zeneca : Crestor, Forxiga, Xigduo (2016)</li> <li>- Merck Sharp &amp; Dohme : Inegy, Atozet (2016)</li> <li>- Sanofi Aventis : Praluent (2016)</li> <li>- Mylan : Pravafenix (2016)</li> <li>- Ferrer Internacional : Provisacor, Omacor (2016)</li> <li>- Amgen : Rephata (2016)</li> </ul>
Pella Daniel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulant drugs (2015)</li> <li>- Amgen : dyslipemia (2015)</li> <li>- Zentiva : dyslipidemia (2015)</li> <li>- Servier : hypertension, coronary artery disease (2015)</li> <li>- Merck Sharp &amp; Dohme : dyslipidemia (2015-2016)</li> <li>- Amgen : dyslipidemia (2016)</li> <li>- Servier : hypertension, dyslipidemia, coronary artery disease (2016)</li> <li>- Pfizer : novel oral anticoagulants (2016)</li> </ul>
Petriashvili Shalva	Nothing to be declared (2015-2016)
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015-2016)</li> </ul>
Pojskic Belma	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : alirocumab (2015-2016)</li> </ul>



## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pojskic Belma	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab (2015-2016)
Postadzhiyan Arman	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2015-2016) - Bayer : AF (2015-2016) - Boehringer-Ingelheim : AF (2015-2016) - Pfizer : AF, dyslipidemia (2015-2016) - Amgen : dyslipidemia (2015-2016) - Sanofi Aventis : dyslipidemia (2015-2016)
Rallidis Loukianos	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Hypolipidemic treatment (2015-2016) - Sanofi Aventis : Hypolipidemic treatment (2015-2016)
Rato Quiteria Agostinho Mateus	Nothing to be declared (2015-2016)
Rigopoulos Angelos	Nothing to be declared (2015-2016)
Rosolova Hana	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Laboratories : antihypertensive drugs, lipid modifying drug (2015-2016) - Servier : antihypertensive drugs (2015-2016) - Mylan : Fenofibrate, Fenofibrate + Ezetimibe, Simvastatin + Fenofibrate (2015-2016) - Amgen : inhibitors of PCSK9 (2015-2016) - Merck Sharp & Dohme : lipid modifying drugs - statin, ezetimibe (2015-2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : inhibitors of PCSK9 (2015-2016)
Ruschitzka Frank	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Drugs (2015-2016) - Sanofi Aventis : Drugs (2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<ul style="list-style-type: none"> <li>- Zoll Medical : LifeVest (2015-2016)</li> <li>- Heartware : Ventricular assist devices (2015-2016)</li> <li>- Amgen : Drug (2016)</li> <li>- Novartis : Drug (2016)</li> <li>- St. Jude Medical : Medical devices (2016)</li> <li>- Cardioentis : TRUE-AHF (2016)</li> <li>- Cardioentis : TRUE-AHF Steering Committee (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> <li>- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> <li>- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Mars : Flavanol-like cocoa products (2015-2016)</li> </ul>
Rynkiewicz Andrzej	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulants (2015)</li> <li>- Amgen : hyperlipidemia (2015)</li> <li>- Sanofi Aventis : hyperlipidemia (2015)</li> <li>- Servier : hypertension (2015)</li> <li>- Amgen Inc : hyperlipidemia (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAC (2016)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Servier : arterial hypertension (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : NOAC (2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Siostrzonek Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lilly : ACS (2015)</li> <li>- Astra Zeneca : ACS (2015-2016)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2015-2016)</li> <li>- Novartis : heart failure (2015-2016)</li> <li>- Amgen : lipid (2015-2016)</li> <li>- Sanofi Aventis : Lipid (2015-2016)</li> <li>- Servier : SCA (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lilly : ACS (2015)</li> <li>- Novartis : heart failure (2015-2016)</li> </ul>
Slapikas Rimvydas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : INFLAMMATION (2015-2016)</li> <li>- Amgen : lipids (2015-2016)</li> <li>- Sanofi Aventis : LIPIDS (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : INFLAMMATION (2015-2016)</li> <li>- Amgen : LIPIDS (2015-2016)</li> <li>- Sanofi Aventis : LIPIDS (2015-2016)</li> </ul>
Sujayeva Volha	Nothing to be declared (2015-2016)
Tunon Fernandez Jose	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : New lipid lowering drugs PCSK9 inhibitors (2015-2016)</li> </ul>
Viigimaa Margus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure (2015-2016)</li> <li>- Boehringer-Ingelheim : Hypertension (2015-2016)</li> <li>- Menarini : Hypertension (2015-2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Viigimaa Margus	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Hypertension, dyslipidemia (2015-2016)</li> <li>- Amgen : Dyslipidemia (2016)</li> </ul>
Visser Laurent	Nothing to be declared (2015-2016)
Von Eckardstein Arnold	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : dyslipidemia (2015)</li> <li>- Sanofi Aventis : dyslipidemia (2015)</li> <li>- Abbott : troponin assays (2015)</li> <li>- Amgen : PCSK9 inhibitors (2016)</li> <li>- Sanofi Aventis : PCSK9 inhibitors (2016)</li> <li>- Merck Sharp &amp; Dohme : Statins and ezitimibe (2016)</li> </ul>
Vrablik Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Amgen : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Pfizer : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Servier : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Sanofi Aventis : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Bristol Myers Squibb : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Genzyme : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : lipid metabolism, CVD prevention (2015-2016)</li> <li>- Mylan : lipid metabolism (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : cardiovascular (2015-2016)</li> </ul>
Wald David	Nothing to be declared (2015-2016)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Weiss Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Amelior (2015-2016)</li> <li>- Astra Zeneca : Antithrombotics (2015-2016)</li> <li>- Boehringer-Ingelheim : doacs (2015-2016)</li> <li>- Vifor International : Ferrinject (2015-2016)</li> <li>- Daiichi Sankyo : Sevikar (2015-2016)</li> <li>- Medtronic : Simplicity System (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS research (2015-2016)</li> <li>- Daiichi Sankyo : Hypertension Research (2015-2016)</li> <li>- Medtronic : hypertension research (2015-2016)</li> </ul>
Williams Bryan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Hypertension (2015-2016)</li> <li>- Daiichi Sankyo : Hypertension (2015-2016)</li> <li>- Novartis : Hypertension (2015-2016)</li> <li>- Servier : Hypertension (2015-2016)</li> <li>- Vascular Dynamics USA : Carotid baroreceptor stent - Advisor and will be Chief Investigator for a pivotal international study in resistant hypertension (2016)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet therapy (2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- Biotronik : Elektrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> </ul>

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>
Wittekoek Janneke	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- LEEFH foundation (cascadescreening FH in the Netherlands) : prevention (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- KPN : e-health (2015-2016)</li> <li>- Amgen : prevention (2015-2016)</li> <li>- Philips : prevention (2015-2016)</li> <li>- MSD : prevention (2016)</li> </ul>
Zavatta Marco	Nothing to be declared (2015-2016)
Zelveian Parounak	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Hypertension (2015-2016)</li> <li>- Egis Pharma : Hypertension (2015-2016)</li> <li>- Pfizer : Hypertension &amp; Atherosclerosis (2015-2016)</li> <li>- Krka Pharma : Hypertension &amp; Atherosclerosis (2015-2016)</li> <li>- Takeda Pharmaceuticals : Hypertension (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Krka Pharma : Hypertension (2016)</li> </ul>
Zimlichman Reuven	Nothing to be declared (2015)

## Guidelines on Dyslipidaemias 2016 (TF33) - REVIEWERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zimlichman Reuven	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pharmaclinical : Clinical research organization (CRO) (2016)



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014-2015-2016)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015-2016)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014-2015-2016)</li> <li>- MSD : Antiplatelet therapy (2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- AbbiVie : cachexia (2016)</li> <li>- Novartis : Heart Failure (2016)</li> </ul>
Achenbach Stephan	<p>Nothing to be declared (2015-2016)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2014)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> <li>- Astra Zeneca : Antiplatelet treatment (2016)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015-2016)</li> <li>- Burson Masteller : nutrition (2014-2015-2016)</li> <li>- Astra Zeneca : thrombosis (2014-2015-2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Badimon Lina	D - Research funding (departmental or institutional). - Astrazeneca : thrombosis (2014-2015-2016)
Baron Esquivias Gonzalo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2014-2015-2016) - Daiichi Sankyo : Anticoagulation (2014-2015-2016) - Pfizer : Anticoagulation (2014-2015-2016) - Bayer : Anticoagulation (2014-2016) - Merck Sharp & Dohme : Dyslipemia (2015-2016)
Baumgartner Helmut	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)
Bax Jeroen	Nothing to be declared (2014-2015-2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin, rivaroxaban (2014)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Pfizer : Apixaban (2014-2015-2016)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015-2016)</li> <li>- Servier : ivabradine (2014-2015-2016)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015-2016)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015-2016)</li> <li>- Janssen-Cilag : GEMINI Trial - RIVAROXACS2002 (2016)</li> <li>- Novartis : Serelaxin, LCZ696, ACZ885, AHF Academy (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2015-2016)</p> <p>E - Research funding (personal). - Astra Zeneca : Ticagrelor (2014-2015-2016)</p>
Carerj Scipione	Nothing to be declared (2014-2015-2016)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014-2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2014-2015-2016)</p>
Fitzsimons Donna	Nothing to be declared (2016)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014) - Amgen : lipid management (2015)
Gaemperli Oliver	Nothing to be declared (2016)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2014) - Pfizer : cardiovascular (2014) - Bristol Myers Squibb : cardiovascular (2014) - Medtronic : cardiovascular (2014-2015) - St Jude Medical : cardiovascular (2014-2015) - Sanofi Aventis : cardiovascular (2014-2015) - Meda pharma : cardiovascular (2014-2015) - Merck Sharp & Dohme : cardiovascular (2014-2015) - Medscape : cardiovascular (2014-2015) - Boehringer-Ingelheim : cardiovascular (2014-2015-2016) - Astra Zeneca : cardiovascular (2015) - Servier : cardiovascular (2015) - Bayer Vital : cardiovascular (2015) - Correvio : cardiovascular (2015) - Bristol Myers Squibb Global : cardiovascular (2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015-2016)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015-2016)</li> <li>- Pfizer Global : cardiovascular (2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : cardiovascular (2014-2015-2016)</li> <li>- St Jude Medical : cardiovascular (2014-2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015-2016)</li> <li>- British Heart Foundation : cardiovascular (2014-2015-2016)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015-2016)</li> <li>- Leducq Foundation : cardiovascular (2014-2015-2016)</li> <li>- European Union FP7 : cardiovascular (2014-2015-2016)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015-2016)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015-2016)</li> <li>- UK Medical Research Council : cardiovascular (2015-2016)</li> </ul> </li> </ul>
Kolh Philippe H	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015-2016)</li> <li>- B.Braun : Surgical instruments (2014-2015-2016)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medtronic : Cardiac valves (2014-2015)</li> <li>- Edwards Lifesciences : Cardiac valves (2014-2015-2016)</li> </ul> </li> </ul>
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> <li>- St Jude Medical : Echo course (2015-2016)</li> <li>- Servier : Ischemic Heart Disease (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015-2016)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Medtronic : AF screening (2016)</li> <li>- BMS/Pfizer : Anticoagulation (2016)</li> <li>- Daiichi-Sankyo : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Bayer/Janssen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015-2016)
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)            - Novartis : Heart Failure Prevention Initiatives (2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Novartis : Heart Failure Prevention Initiatives (2015-2016)</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardiorentis : heart failure (2014-2015-2016)</li> <li>- Vifor Pharma Ltd : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Amgen : heart failure, lipids (2014-2015-2016)</li> <li>- BioControl : devices (2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)</li> <li>- Respicardia : devices (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Respicardia : anticoagulant (2014-2015-2016)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardioentis : heart failure (2014-2015-2016)</li> <li>- Bayer Healthcare : heart failure (2014-2015-2016)</li> <li>- CIBIEM : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Celladon : heart failure (2015)</li> <li>- BioControl : devices (2015-2016)</li> <li>- DC Device : devices (2015-2016)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015-2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)</li> <li>- Terumo Inc : coronary catheters (2016)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015-2016)</li> <li>- Boston Scientific : devices (2014-2015-2016)</li> <li>- Medtronic : devices (2014-2015-2016)</li> <li>- Biotronik : devices (2014-2015-2016)</li> <li>- Abbott Vascular : devices (2014-2015-2016)</li> <li>- Terumo Inc : devices (2015-2016)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015-2016)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015-2016)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015-2016)</li> <li>- Sanofi Aventis : anticoagulants (2015-2016)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015-2016)</li> <li>- United Therapeutics : pulmonary hypertension (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015-2016)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet therapy (2014)</li> <li>- Bayer Healthcare : Antithrombotic drug (2014)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Abbott : Stent and Heartvalvetherapy (2014)</li> <li>- Biosensors : Stents (2014)</li> <li>- Boston Scientific : Stents (2014)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Antithrombotic therapy (2014)</li> <li>- Johnson &amp; Johnson : Catheters (2014)</li> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- Biotronik : Elektrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul>